BMS CA224-098, RELATIVITY 098 (Melanoma)

What is the Purpose of this Study?

If you choose to join this study, you will:
- Be randomly assigned (like a coin flip) to 1 of 2 groups
-- One group will get relatlimab + nivolumab after surgery
-- The other group will get nivolumab on its own after surgery
- Both groups will get dosed every 4 weeks by intravenous (IV) infusion for up to 1 year
What is the Condition Being Studied?
Melanoma

Who Can Participate in this Study?

Adults ages 18+ who:

- Are diagnosed with stage III or 4 melanoma

- Have had their tumor(s) completely removed

For more information about who can join this study, please contact the study team at ivy.belskie@duke.edu.

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to find out if combining 2 drugs (relatlimab + nivolumab) is more effective than using nivolumab on its own to prevent a recurrence of melanoma. Currently, using nivolumab on its own is the standard treatment to prevent melanoma from coming back after it has been removed by surgery.

Study Details

Full Title
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
Principal Investigator

Protocol Number
IRB:
PRO00109246

NCT:
NCT05002569
ClinicalTrials.gov
View on ClinicalTrials.gov